Walley T, Winstanley P, Roberts D, Grimmer M, Orme M, Breckenridge A
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
Postgrad Med J. 1990 Feb;66(772):106-9. doi: 10.1136/pgmj.66.772.106.
Hypertensive patients prescribed captopril while attending a hospital hypertension clinic were studied, to identify the benefits of the drug, its adverse effects and factors predisposing to them. One hundred and eighty two patients were followed for a mean of 18 months; 24 received captopril alone, and 158 combinations of captopril and other antihypertensive drugs, especially loop diuretics (91/158), or thiazide diuretics (57/158), or other vasodilators (57/158). The mean final dose of captopril was 67 mg/day. Blood pressure (BP) was effectively controlled in 73% of patients (mean fall in systolic BP 29 mmHg, CI 24 to 34, P less than or equal to 0.001; mean fall in diastolic BP 18 mmHg, CI 16 to 20, P less than or equal to 0.001). Blood urea and creatinine rose slightly in all patients (urea by 0.9 mmol/l [13%], CI 0.5-1.3, P less than or equal to 0.001 and creatinine by 9 mumols/l [8%], CI 4-13, P less than or equal to 0.001). Twenty six patients were withdrawn from captopril therapy: 6 because of poor control of their blood pressure, two because it was no longer necessary and 12 (7.7%) because of extrarenal adverse effects--10 for rashes, one each for gastric upset and impotence. Captopril was withdrawn in a further 6 patients, because of deteriorating renal function. Factors discriminating those at risk of renal dysfunction were high doses of captopril, concomitant high dose diuretic therapy and undiagnosed renovascular disease.
对在医院高血压门诊就诊并服用卡托普利的高血压患者进行了研究,以确定该药物的益处、不良反应以及导致这些不良反应的因素。182名患者被随访了平均18个月;24名患者单独服用卡托普利,158名患者服用卡托普利与其他抗高血压药物的组合,尤其是襻利尿剂(91/158)、噻嗪类利尿剂(57/158)或其他血管扩张剂(57/158)。卡托普利的平均最终剂量为67毫克/天。73%的患者血压得到有效控制(收缩压平均下降29毫米汞柱,可信区间24至34,P≤0.001;舒张压平均下降18毫米汞柱,可信区间16至20,P≤0.001)。所有患者的血尿素和肌酐均略有升高(尿素升高0.9毫摩尔/升[13%],可信区间0.5 - 1.3,P≤0.001;肌酐升高9微摩尔/升[8%],可信区间4 - 13,P≤0.001)。26名患者停止了卡托普利治疗:6名是因为血压控制不佳,2名是因为不再有必要,12名(7.7%)是因为肾外不良反应——10名是因为皮疹,1名是因为胃部不适,1名是因为阳痿。另有6名患者因肾功能恶化而停用卡托普利。区分有肾功能障碍风险患者的因素是高剂量的卡托普利、同时进行的高剂量利尿剂治疗以及未诊断出的肾血管疾病。